Patient and disease characteristics
| Characteristic . | Patients from ASPEN study who transitioned to zanubrutinib (N = 47) . | |
|---|---|---|
| At parent study enrollment: BGB-3111-302 (ASPEN) . | At LTE enrollment: BGB-3111-LTE1 (LTE1) . | |
| Age, median (range), y | 68 (38-84) | 73 (44-89) |
| <65, n (%) | 16 (34) | 8 (17) |
| ≥65, n (%) | 22 (46.8) | 21 (44.7) |
| ≥75, n (%) | 9 (19.1) | 18 (38.3) |
| Male sex, n (%) | 34 (72.3) | 34 (72.3) |
| Pre-BTK inhibitor treatment status, n (%) | ||
| Treatment naive | 10 (21.3) | |
| Relapsed/refractory | 37 (78.7) | |
| Previous lines of therapy, median (range) | 1 (1-6) | |
| ECOG performance status, n (%) | ||
| 0 | 25 (53) | 27 (57.4) |
| 1 | 21 (45) | 17 (36.2) |
| 2 | 1 (2.1) | 1 (2.1) |
| Missing | 0 | 2 (4.3) |
| CXCR4 mutation status, n (%) | ||
| WHIM FS | 5 (10.6) | |
| WHIM NS | 2 (4.3) | |
| WT | 38 (80.9) | |
| Unknown | 2 (4.3) | |
| TP53 mutation, n (%) | 8 (17.0) | |
| Characteristic . | Patients from ASPEN study who transitioned to zanubrutinib (N = 47) . | |
|---|---|---|
| At parent study enrollment: BGB-3111-302 (ASPEN) . | At LTE enrollment: BGB-3111-LTE1 (LTE1) . | |
| Age, median (range), y | 68 (38-84) | 73 (44-89) |
| <65, n (%) | 16 (34) | 8 (17) |
| ≥65, n (%) | 22 (46.8) | 21 (44.7) |
| ≥75, n (%) | 9 (19.1) | 18 (38.3) |
| Male sex, n (%) | 34 (72.3) | 34 (72.3) |
| Pre-BTK inhibitor treatment status, n (%) | ||
| Treatment naive | 10 (21.3) | |
| Relapsed/refractory | 37 (78.7) | |
| Previous lines of therapy, median (range) | 1 (1-6) | |
| ECOG performance status, n (%) | ||
| 0 | 25 (53) | 27 (57.4) |
| 1 | 21 (45) | 17 (36.2) |
| 2 | 1 (2.1) | 1 (2.1) |
| Missing | 0 | 2 (4.3) |
| CXCR4 mutation status, n (%) | ||
| WHIM FS | 5 (10.6) | |
| WHIM NS | 2 (4.3) | |
| WT | 38 (80.9) | |
| Unknown | 2 (4.3) | |
| TP53 mutation, n (%) | 8 (17.0) | |
ECOG, Eastern Cooperative Oncology Group; FS, frameshift mutation; NS, nonsense mutation; WHIM, warts, hypogammaglobulinemia, infections, myelokathexis; WT, wild type.